RxDoctor Payments DataLook up a doctor →

Ayman Tarabishy, MD

Pain Medicine · Livonia, MINPI 1568751550

Payments from drug & device makers

$15,625in general payments, 2019–2025

Across 486 payments — averaging $32.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Boston Scientific$2K
  • Nevro Corp.$2K
  • AbbVie$2K
  • Vertos Medical, Inc.$1K
  • Nalu Medical, Inc.$429
  • plus $4K from 38 others

What the payments were for

  • Travel & lodging$1,3619%
  • Food & beverage$13,81488%
  • Education$4503%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,625 in reported general payments places this provider in the 85th percentile of 139 pain medicine providers in Michigan.

See all pain medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$209,100
Medicare patients
274
Services billed
4,173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl32$26,395
RelistorMethylnaltrexone Bromide12$26,168
Buprenorphine44$12,261
HorizantGabapentin Enacarbil12$6,576
MovantikNaloxegol Oxalate15$5,996
Diclofenac Sodium80$4,059
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen306$4,012
Gabapentin211$3,378
Lidocaine33$2,676
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$2,586
Tizanidine Hcl127$2,404
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen98$2,246
Pregabalin95$2,067
Calcitonin-SalmonCalcitonin,salmon,synthetic15$1,100
Baclofen59$939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$286$26,39532 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$218$26,16812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 139 pain medicine providers in Michigan.

Other pain medicine in Livonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →